Nine-valent human papilloma virus vaccine and application thereof

• Main Authors: GAO JUN, ZHANG HAIJIANG, YIN FEI, JIANG XULIN, YU HONGYANG, LIU YUYING, WU SHUMING, WANG XUEHONG, XUE JUNLIAN, FENG HUIBIN, JIANG LIRONG, LI LING, GAO WENSHUANG, SHEN ERCUI, LYU MUZI, CHEN XIAO, LIU YONGJIANG, SHI YAZHENG, ZHANG JIATAO
• Format: Patent
• Language: Chinese; English
• Published: 24.05.2024
• Subjects: HUMAN NECESSITIES; HYGIENE; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MEDICAL OR VETERINARY SCIENCE; NANOTECHNOLOGY; PERFORMING OPERATIONS; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS; SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; TRANSPORTING

The invention relates to the field of medicines, and particularly discloses a nine-valent human papilloma virus vaccine and application thereof. The nine-valent human papilloma virus vaccine comprises truncated L1-VLP antigens of HPV6, HPV11, HPV16, HPV18, HPV31, HPV33, HPV45, HPV52 and HPV58, and an aluminum hydroxide adjuvant. The antigen components in the nine-valent HPV vaccine provided by the invention all come from the main capsid protein L1 of HPV and are truncated, and through the truncated L1 protein expressed by an escherichia coli system, the yield of the L1 protein is improved, and the production cost of the vaccine is reduced. By optimizing the particle size of each type of VLP antigen and the particle size of the aluminum hydroxide adjuvant and combining and controlling the ratio of each type of VLP antigen to the aluminum hydroxide adjuvant, the obtained nine-valent HPV vaccine induces high-level immune response, especially shows an obvious effect clinically, and is superior to the effect of re